ABSTRACT
The purpose of this study was to explore the copy number variations (CNVs) associated with miscarriage. A total of 662 specimens of aborted embryonic tissue and 54 samples from peripheral blood were collected. Next generation sequencing for CNV analysis was performed to determine the type and clinical significance of possible CNVs, and relevant medical records were collected. Autosomal trisomy, both single and multiple, was the most common abnormality (207 cases, 63.5% of abnormalities). Trisomy 16 was the most frequent single trisomy, followed by trisomy 22, trisomy 15 and trisomy 21. The rate of chromosomal abnormalities of fetuses in early pregnancy (65.4%) was higher than that of fetuses in middle pregnancy (16.4%). There were 82 pregnant women with recurrent abortion, and the embryo with pathogenic CNVs was conceived in 62 (76%) cases, while the embryo with variants of unknown significance (VUS) in 12 (15%) cases. Among the 27 couples with a history of recurrent pregnancy loss (RPL), there were 4 (14.8%) couples with CNV abnormal in both partners, 16 (59.3%) couples with CNV abnormal only in the women, and 7 (25.9%) couples with CNV abnormal only in the men. These retrospective analyses of CNV-seq results provided a reference for genetic counseling of the relationship between VUS and RPL.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was performed under the guidance of the Declaration of Helsinki and approved by the Ethics Committee of Zhongnan Hospital of Wuhan University (Ethics No.2023049K).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
